Abstract 1793
Background
Changes to the AJCC melanoma staging system eighth edition (AJCC-8) should be independently validated to assess its prognostic performance compared with the seventh edition (AJCC-7) in accurately staging melanoma.
Methods
We used the SEER-18 registry from 2010 to 2015 to extract patient-, tumour-related and survival data. Kaplan-Meier analysis was used for overall survival (OS) and cancer-specific survival (CSS) for AJCC-7 and AJCC-8. Cumulative hazard functions were computed using Nelson-Aalen function.
Results
Of 126,408 individuals, 59,989 (47%) and 60,411 (48%) had available data for pathological and clinical stage OS analysis, respectively. The 12-month OS for AJCC-7 among pathologically staged patients were: stage IA 99%, stage IB 99%, stage IIA 96%, stage IIB 94%, stage IIC 87%, stage IIIA 98%, stage IIIB 94%, stage IIIC 82% and stage IV 41%. The 12-month OS for AJCC-8 patients was similar to AJCC-7 but was 88% for stage IIIC and 65% for stage IIID. The 12-month risk of dying for pathological stage IIIC was 13% compared to 41% for pathological stage IIID (p < 0.001). Stage IV individuals with an elevated LDH had worse OS and CSS at all other measured time-points up to 60 months compared to those with a normal LDH. Stage IV individuals with brain metastases (M1d) also had worse OS and CSS at all other measured time-points up to 60 months compared to other stage IV subgroups.
Conclusions
The discriminatory ability of the AJCC-7 and AJCC-8 melanoma staging system appear comparable. Changes in AJCC-8 identifies individuals with a poorer prognostic within new subgroups. These include the subgroups of stage IIID and M1d within stage IV individuals, and the addition of elevated LDH as a prognostic marker in stage IV disease. However, advanced T stage, node-negative tumours experienced worse survival compared with earlier T stage, node-positive tumours requiring further research to evaluate the underlying biology of these tumour subgroups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract